According to the current NCCN guideline for NSCLC [33], contraindications for treatment with PD-1/PD-L1 inhibitors may include active or previously documented autoimmune disease and/or current use of immunosuppressive agents or the presence of an oncogene, which would predict a lack of benefit. This evidence concerns the gene CD274 and non-small cell lung carcinoma.